Literature DB >> 17268838

The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review.

Eldo E Frezza1, Mitchell S Wachtel, Maurizio Chiriva-Internati.   

Abstract

By itself, glucagon-like peptide-1(GLP-1) appears to be an excellent drug for appetite control and the treatment of obesity. Unfortunately, few enzymes, such as IV dipeptidyl peptidase and renal excretin, degrade and render GLP-1 inactive within minutes. A receptor agonist, exendin-4, with a longer biological half-life than GLP-1, has been tried. Subcutaneous injection of exendin-4 or continuous IV injection of GLP-1 warrants further research and investigation.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17268838     DOI： 10.1007/s10620-006-9096-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.487


  84 in total

1.  Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas.

Authors:  Ramona A Silvestre; Jovita Rodríguez-Gallardo; Eva M Egido; J Marco
Journal:  Eur J Pharmacol       Date:  2003-05-23       Impact factor: 4.432

2.  Ghrelin enhances appetite and increases food intake in humans.

Authors:  A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

3.  Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus.

Authors:  L Rinaman
Journal:  Am J Physiol       Date:  1999-08

4.  A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

Authors:  TracyAnn Perry; Debomoy K Lahiri; Demao Chen; Jie Zhou; Karen T Y Shaw; Josephine M Egan; Nigel H Greig
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

5.  Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells.

Authors:  P G Andreis; L K Malendowicz; G Neri; C Tortorella; G G Nussdorfer
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 6.  Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success?

Authors:  Ermenegildo Eldo Frezza
Journal:  Obes Surg       Date:  2004-08       Impact factor: 4.129

7.  CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors.

Authors:  Kimberly P Kinzig; David A D'Alessio; James P Herman; Randall R Sakai; Torsten P Vahl; Helmer F Figueiredo; Erin K Murphy; Randy J Seeley; Helmer F Figueredo
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

8.  Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

Authors:  K Meeran; D O'Shea; C M Edwards; M D Turton; M M Heath; I Gunn; S Abusnana; M Rossi; C J Small; A P Goldstone; G M Taylor; D Sunter; J Steere; S J Choi; M A Ghatei; S R Bloom
Journal:  Endocrinology       Date:  1999-01       Impact factor: 4.736

9.  Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect.

Authors:  Ludwik K Malendowicz; Gastone G Nussdorfer; Krzysztof W Nowak; Agnieszka Ziolkowska; Cinzia Tortorella; Marcin Trejter
Journal:  Int J Mol Med       Date:  2003-08       Impact factor: 4.101

10.  Human distribution and release of a putative new gut hormone, peptide YY.

Authors:  T E Adrian; G L Ferri; A J Bacarese-Hamilton; H S Fuessl; J M Polak; S R Bloom
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682
View more
  14 in total

1.  Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat diet.

Authors:  Kaori Fujiwara; Takuya Inoue; Yujiro Henmi; Yoshimasa Hirata; Yutaka Naka; Azusa Hara; Kazuki Kakimoto; Sadaharu Nouda; Toshihiko Okada; Ken Kawakami; Toshihisa Takeuchi; Kazuhide Higuchi
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

2.  Laparoscopic sleeve gastrectomy: a first step for rapid weight loss in morbidly obese patients requiring a second non-bariatric procedure.

Authors:  Jesus E Hidalgo; Mayank Roy; Alexander Ramirez; Samuel Szomstein; Raul J Rosenthal
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

3.  Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction.

Authors:  Sarah Evans; Zehra Pamuklar; Jonathan Rosko; Patrick Mahaney; Ning Jiang; Chan Park; Alfonso Torquati
Journal:  Surg Endosc       Date:  2011-11-02       Impact factor: 4.584

4.  The changes of pro-opiomelanocortin neurons in type 2 diabetes mellitus rats after ileal transposition: the role of POMC neurons.

Authors:  Weijie Chen; Zhibo Yan; Shaozhuang Liu; Guangyong Zhang; Dong Sun; Sanyuan Hu
Journal:  J Gastrointest Surg       Date:  2011-06-30       Impact factor: 3.452

Review 5.  Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review.

Authors:  Lauren M Beckman; Tiffany R Beckman; Carrie P Earthman
Journal:  J Am Diet Assoc       Date:  2010-04

6.  Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model.

Authors:  Chuan-an Shen; Shawn Fagan; Alan J Fischman; Edward E Carter; Jia-Ke Chai; Xiao-Ming Lu; Yong-Ming Yu; Ronald G Tompkins
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

Review 7.  Laparoscopic vertical sleeve gastrectomy for morbid obesity. The future procedure of choice?

Authors:  Eldo E Frezza
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

Review 8.  Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin.

Authors:  Eldo E Frezza; Maurizio Chiriva-Internati; Mitchell S Wachtel
Journal:  Surg Today       Date:  2008-05-31       Impact factor: 2.549

Review 9.  Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

Authors:  Rania Abu-Hamdah; Atoosa Rabiee; Graydon S Meneilly; Richard P Shannon; Dana K Andersen; Dariush Elahi
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

10.  The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.

Authors:  Panagis Galiatsatos; B Robert Gibson; Atoosa Rabiee; Olga Carlson; Josephine M Egan; Richard P Shannon; Dana K Andersen; Dariush Elahi
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.